[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-cell-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-cell-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,81,101,112,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053511","chaamp-charlotte-advocate-mgus-project-internal-pilot-study-100053511",false,"NCT06644625","CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study","SCREENING Inclusion Criteria:\n\n* Age 30 years or older at the time of consent\n* Either:\n\n  1. Self-identify as Black and\u002For African American OR\n  2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia\n* Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately\n* Reside in Charlotte, NC, or the surrounding area, based on self-report\n\nSCREENING Exclusion Criteria:\n\n* Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.\n\nLONGITUDINAL Inclusion Criteria:\n\n* Test positive for monoclonal gammopathy during screening portion of the study\n* Consent to the longitudinal portion of the study\n\nLONGITUDINAL Exclusion Criteria:\n\n* The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.",true,"ALL","30 Years",{"count":19,"type":20},1665,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.",[24,25,26,27,28],"Multiple Myeloma","Multiple Myeloma Progression","Monoclonal Gammopathy of Undetermined Significance (MGUS)","Smoldering Multiple Myeloma (SMM)","Plasma Cell Disorders",[30,31,32],"multiple myeloma","hematology","plasma cell disorders","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-03-01",{"date":41,"type":20},"2035-01",{"name":43,"class":44},"Wake Forest University Health Sciences","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100642057","phase-1-gprc5d-targeted-petct-imaging-in-plasma-cell-disorders-100642057","NCT07660939","GPRC5D Targeted PET\u002FCT Imaging in Plasma Cell Disorders","A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET\u002FCT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders","Inclusion Criteria:\n\n* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.\n* Healthy volunteers eligible for PET\u002FCT imaging may also be enrolled.\n* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.\n* Ability to undergo PET\u002FCT imaging procedures.\n* Ability to understand the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* History of other active malignant tumors, unless considered clinically insignificant by the investigator.\n* Pregnant or breastfeeding women.\n* Inability to understand study procedures or comply with imaging examinations.\n* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.","18 Years","80 Years",{"count":56,"type":20},50,"INTERVENTIONAL",[59],"PHASE1","This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET\u002FCT imaging in patients with plasma cell disorders, including multiple myeloma.\n\nParticipants will undergo GPRC5D-targeted PET\u002FCT, 18F-FDG PET\u002FCT, and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.\n\nThe study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET\u002FCT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.",[28,62],"Multiple Myeloma (MM)",[64,65,66,67,30,68,69,70],"targeted imaging","molecular imaging","GPRC5D","precise oncology","PET\u002FCT","nuclear medicine","precise diagnosis","NOT_YET_RECRUITING","2026-06-16",{"date":74,"type":37},"2026-06-22",{"date":76,"type":20},"2026-06-25",{"date":78,"type":20},"2027-05-25",{"name":80,"class":44},"Peking University First Hospital",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100535524","gut-microbiome-studies-in-patients-with-poems-syndrome-and-other-plasma-cell-disorders-100535524","NCT06252948","Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders","Microbiome","Inclusion Criteria:\n\n* Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloid light chain (AL) amyloidosis or healthy controls from their households\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy\n* Substance abuse\n* Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation\n* Chronic gastrointestinal disorder\n* Gastrointestinal surgeries in the past 2 years\n* Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)",{"count":89,"type":20},240,"A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders",[28],"2026-02-19",{"date":94,"type":37},"2026-02-23",{"date":96,"type":37},"2021-12-29",{"date":98,"type":20},"2028-12-29",{"name":100,"class":44},"Mayo Clinic",{"id":102,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":104,"keywords":105,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":111,"locationsCount":45},"100565626",{"count":19,"type":20},[24,25,26,27,28],[30,31,32],"2026-01-15",{"date":108,"type":37},"2026-01-20",{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":57,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":45},"100601835","phase-2-radiation-combined-with-bcmacd3-bispecific-antibody-therapy-for-solitary-bone-plasmacytoma-with-mild-bone-marrow-infiltration-100601835","NCT07115667","Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically confirmed SBP with \\\u003C10% clonal plasma cells in marrow\n* ECOG ≤ 2\n* No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.\n* Meets laboratory and imaging criteria\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.\n2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","78 Years",{"count":121,"type":20},21,[123],"PHASE2","This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.",[126,127,28],"Solitary Bone Plasmacytoma","Plasmacytoma of Bone",[129,130],"solitary bone plasmacytoma","BCMA\u002FCD3 bispecific antibody","2025-09-05",{"date":133,"type":37},"2025-09-08",{"date":135,"type":37},"2025-08-25",{"date":137,"type":20},"2027-12-01",{"name":139,"class":44},"Institute of Hematology & Blood Diseases Hospital, China",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":147,"targetDuration":149,"studyType":21,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100538083","registry-of-patients-with-plasma-cell-disorders-100538083","NCT06286215","Registry of Patients With Plasma Cell Disorders","Registry PCD","Inclusion Criteria:\n\n* Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014\n* Aged 18 years and above\n\nExclusion Criteria:\n\n* insufficient data needed for analysis",{"count":148,"type":20},750,"10 Years","The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:\n\n* The incidence of plasma cell disorders both before and after malignancy\n* Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)\n* Progression free survival (PFS)\n* overall survival\n* factors influencing overall survival, progression-free survival, and time to progression\n* Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients.\n* genetic characteristics of plasma cell disorder\n* cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.",[28],[153,154],"registry","plasma cell disorder","2024-02-22",{"date":157,"type":37},"2024-02-29",{"date":159,"type":20},"2024-04-01",{"date":161,"type":20},"2035-04-01",{"name":163,"class":44},"Siriraj Hospital"]